Objective: Our study aims to investigate and determine the sclerostin levels in blood and saliva of patients with scleroderma (systemıc sclerosis) and to compare their levels with those of healthy volunteers. In the literature, there is no sufficient number of studies that demonstrate the association between scleroderma and sclerostin. Sclerostin is thought to play a role in the pathogenesis of scleroderma.

Material and Method: In our study, 35 scleroderma patients and 35 healty volunteers were enrolled. Blood and saliva sclerostin levels of the patient and healthy controls were measured.

Results: The level of sclerostin in blood and saliva of the scleroderma group was measured to be significantly higher than in the control group (p <0,05).

Conclusion: The level of sclerostin increases in scleroderma that is a chronic autoimmune disease. Sclerostin is an inhibitor of Wnt signaling pathway. These results may point that sclerostin or Wnt pathway have a role in the pathogenesis of scleroderma. However further studies involving more participants are needed in order to verify this hypothesis.